A new study published in the International Journal of Molecular Sciences investigates the potential of Mitragyna speciosa (commonly known as kratom) in addressing Alzheimer’s disease (AD), a neurodegenerative condition with limited treatment options.
The research, conducted by teams from Walailak University in Thailand, the University of Kentucky, and the University of Chittagong in Bangladesh, employed network pharmacology, molecular docking, and in vitro methods to explore the plant’s therapeutic mechanisms.
Mitragyna speciosa has long been used traditionally for pain relief, hypertension, cough suppression, and addiction recovery. In this study, researchers identified 19 compounds from the plant that interact with 60 AD-related targets. A compound-target network revealed significant connections among 60 nodes and 470 edges, highlighting the multi-faceted nature of these interactions. Pathway enrichment analysis identified Alzheimer’s disease (hsa05010) as a key pathway affected by these compounds.
Docking studies further demonstrated strong binding affinities between Mitragyna speciosa compounds—such as acetylursolic acid, beta-sitosterol, isomitraphylline, and speciophylline—and proteins linked to AD, including AKT1, GSK3B, NFκB1, and BACE1. In vitro experiments revealed that plant extracts significantly reduced oxidative stress in H2O2-induced SH-SY5Y cells, an Alzheimer’s disease cell model.
“This research underscores the multi-component, multi-target, and multi-pathway effects of MS on AD, providing insights for future research and potential clinical applications”, concludes the study.
The study’s full text can be found here.
More articles from The Marijuana Herald can be found below.
